Heat, not surgery: new trial aims to cure thyroid cancer without a knife

NCT ID NCT07376837

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether radiofrequency ablation (using heat) can safely cure small, low-risk thyroid cancers without surgery. Thirty adults who decline surgery or active monitoring will receive the treatment and be followed for a year. The goal is to see if the cancer is completely gone after treatment, offering a less invasive option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Histologically confirmed papillary thyroid carcinoma (PTC) by fine-needle aspiration (FNA -Bethesda V/VI ) or core needle biopsy. * Single or multiple lesions, each 2.0 cm in maximum diameter. * Intrathyroidal tumors (i.e., no extrathyroidal extension, no clinical/radiological evidence of nodal metastases, nor distant metastases). * Lesions located at a safe distance (\>2 mm) from critical structures (e.g., trachea, esophagus, carotid artery) or accessible with hydrodissection. * ≤T1b (i.e. \< 2cm maximal diameter), N0 or Nx, M0 (no clinical or radiological evidence of lymph node or distant metastasis). * Patients unfit for surgery due to comorbidities or who refuse surgery. * ≥18 years old * Not pregnant at the time of RFA. * Able to understand and voluntarily sign informed consent. Exclusion Criteria: * Evidence of lymph node involvement (clinically or radiologically suspicious or confirmed metastatic nodes) or distant metastasis (e.g., lung, bone). * Tumors with extrathyroidal extension * Tumors with extensive calcification * Tumors located within 2 mm of critical structures where RFA would pose an unacceptably high risk and where hydrodissection is not feasible. * Previous thyroid surgery or ablation (RFA, ethanol, laser, or microwave) at the index tumor site. * Known diagnosis of anaplastic, poorly differentiated, or other aggressive thyroid cancer variants. * Pregnant or breastfeeding at the time of enrollment. * Bleeding diathesis or use of anticoagulants that cannot be discontinued safely prior to RFA. * Severe comorbid illness that limits life expectancy to less than 5 years. * Inability to adhere to study follow-up schedule or procedures or lacking decision-making capacity. * Implanted electrical devices such as pacemakers or neurostimulators * Infection in the neck including skin infection or thyroiditis at time of planned ablation. * Severe cervical anatomy distortion (prior neck surgery or radiation with distorted anatomy that prevents safe RFA

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thyroid papillary carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Thyroid Cancer, Papillary thyroid gland papillary carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Health Network - Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.